title: Hormonal, renal, and metabolic alterations during hypertension induced by chronic inhibition of NO in rats.
abstract: The evolution of renal excretory function and circulating vasoactive systems was studied during progressive increases in blood pressure (BP) induced in rats by oral administration of NG-nitro-L-arginine methyl ester (L-NAME; 5-30 mg/100 ml) for 5 wk. L-NAME induced a stepped elevation (P < 0.05) in BP levels without changing creatinine clearance, urine flow, or sodium excretion rate along the study. Reductions (P < 0.05) in plasma renin activity and plasma aldosterone concentration were found only during treatment with 30 mg/100 ml of L-NAME. Plasma norepinephrine and epinephrine concentrations were elevated (P < 0.05) in the last week of the study. Plasma concentrations of endothelin-1 and urinary excretion of prostaglandin E2, 6-ketoprostaglandin F1 alpha, and thromboxane B2 were not significantly affected by L-NAME. Similarly, no changes in plasma concentrations of glucose, insulin, total cholesterol, or triglycerides were observed. In summary, during long-term administration of L-NAME, progressive increases in BP levels were observed without changes in either sodium excretion or enhanced circulating vasoconstrictor activity. Thus, it is likely that inhibition of synthesis of nitric oxide (NO) in the vasculature leads to an imbalance between the tonic relaxing action of NO and the influences of vasoconstrictor agents even when the latter remain at normal levels.
authors.affiliation: Department of Physiology, Complutense University, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Navarro
authors.forename: A
authors.initials: A
authors.lastname: Sanchez
authors.forename: J
authors.initials: J
authors.lastname: Sáiz
authors.forename: L M
authors.initials: LM
authors.lastname: Ruilope
authors.forename: J
authors.initials: J
authors.lastname: García-Estań
authors.forename: J C
authors.initials: JC
authors.lastname: Romero
authors.forename: S
authors.initials: S
authors.lastname: Moncada
authors.forename: V
authors.initials: V
authors.lastname: Lahera
mesh_terms: D000450:Aldosterone / Q000097:blood; D000594:Amino Acid Oxidoreductases / Q000037:antagonists & inhibitors; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D004231:Diuresis / Q000187:drug effects; D004298:Dopamine / Q000097:blood; D004837:Epinephrine / Q000097:blood; D006973:Hypertension / Q000503:physiopathology*; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D019331:NG-Nitroarginine Methyl Ester; D009318:Natriuresis; D009569:Nitric Oxide / Q000037:antagonists & inhibitors*; D019001:Nitric Oxide Synthase; D009638:Norepinephrine / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000097:blood
chemical_list: D009569:Nitric Oxide; D000450:Aldosterone; D001120:Arginine; D003404:Creatinine; D019001:Nitric Oxide Synthase; D000594:Amino Acid Oxidoreductases; D012083:Renin; D019331:NG-Nitroarginine Methyl Ester; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine